Related references
Note: Only part of the references are listed.Eicosapentaenoic acid attenuates renal lipotoxicity by restoring autophagic flux
Takeshi Yamamoto et al.
AUTOPHAGY (2021)
Plant -Based Diets, the Gut Microbiota, and Trimethylamine N -Oxide Production in Chronic Kidney Disease: Therapeutic Potential and Methodological Considerations
Gretchen N. Wiese et al.
JOURNAL OF RENAL NUTRITION (2021)
Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015
Hui-Teng Cheng et al.
DIABETES CARE (2021)
Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice
Wenchao Zhang et al.
SCIENTIFIC REPORTS (2021)
The Effect of Chickpea Dietary Fiber on Lipid Metabolism and Gut Microbiota in High-fat Diet-induced Hyperlipidemia in Rats
Jia Han et al.
JOURNAL OF MEDICINAL FOOD (2021)
Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
R. Scott Wright et al.
MAYO CLINIC PROCEEDINGS (2020)
Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD
Julio Alejandro Lamprea-Montealegre et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Boris Bikbov et al.
LANCET (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Yi-Chih Lin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Electronegative LDL Induces M1 Polarization of Human Macrophages Through a LOX-1-Dependent Pathway
Shwu-Fen Chang et al.
INFLAMMATION (2020)
Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study
Chieh-Li Yen et al.
DIABETES CARE (2020)
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
Jose Tunon et al.
EUROPEAN HEART JOURNAL (2020)
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
Matthew J. Budoff et al.
EUROPEAN HEART JOURNAL (2020)
Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites
Timothy D. O'Connell et al.
EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)
Defining Myocardial Abnormalities Across the Stages of Chronic Kidney Disease A Cardiac Magnetic Resonance Imaging Study
Manvir K. Hayer et al.
JACC-CARDIOVASCULAR IMAGING (2020)
Short-Chain Fatty Acids and Their Association with Signalling Pathways in Inflammation, Glucose and Lipid Metabolism
Jin He et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Alterations of the Human Gut Microbiome in Chronic Kidney Disease
Zhigang Ren et al.
ADVANCED SCIENCE (2020)
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk The STRENGTH Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Lipoprotein(a) and PCSK9 inhibition: clinical evidence
Massimiliano Ruscica et al.
EUROPEAN HEART JOURNAL SUPPLEMENTS (2020)
Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006-2016
Min-Hao Lin et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis
Lathan Liou et al.
PLOS ONE (2020)
Green tea leaf powder prevents dyslipidemia in high-fat diet-fed mice by modulating gut microbiota
Jin Wang et al.
FOOD & NUTRITION RESEARCH (2020)
Resveratrol improves lipid metabolism in diabetic nephropathy rats
Yong-hong Zhao et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2020)
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
Jose Tunon et al.
EUROPEAN HEART JOURNAL (2020)
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor- Modulator (SPPARM), in Dyslipidemic Patients with Renal Impairment
Koutaro Yokote et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials
Manuela Casula et al.
PHARMACOLOGICAL RESEARCH (2019)
An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients
Marcelino Bermudez-Lopez et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
David M. Charytan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3
Agnes Nemeth et al.
BMC NEPHROLOGY (2019)
Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses
Francisco Herrera-Gomez et al.
SCIENTIFIC REPORTS (2019)
Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate
Yusuke Sasaki et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients
Michael Lawrenz F. Co et al.
AMERICAN JOURNAL OF CARDIOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy et al.
CIRCULATION (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety
Edward Lee et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment (vol 14, pg 57, 2017)
Shipra Agrawal et al.
NATURE REVIEWS NEPHROLOGY (2018)
Strategies to manage cardiovascular risk in chronic kidney disease
Patrick B. Mark
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy
Habib Yaribeygi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
The role of lipoprotein (a) in chronic kidney disease
Jemma C. Hopewell et al.
JOURNAL OF LIPID RESEARCH (2018)
Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease
Milica Miljkovic et al.
CLINICAL BIOCHEMISTRY (2018)
Trimethylamine N-Oxide: A Link among Diet, Gut Microbiota, Gene Regulation of Liver and Intestine Cholesterol Homeostasis and HDL Function
Marina Canyelles et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation
Elani Streja et al.
JAMA NETWORK OPEN (2018)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway
Toshinobu Maki et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2017)
Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit
Fernando Brites et al.
BBA CLINICAL (2017)
Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease Findings From the CRIC Study (Chronic Renal Insufficiency Cohort)
Archna Bajaj et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
L5-LDL from ST-elevation myocardial infarction patients induces IL-1β production via LOX-1 and NLRP3 inflammasome activation in macrophages
Tzu-Ching Yang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2017)
HDL abnormalities in nephrotic syndrome and chronic kidney disease
Nosratola D. Vaziri
NATURE REVIEWS NEPHROLOGY (2016)
Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis
Xiaole Su et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis
Nathalie Hennuyer et al.
ATHEROSCLEROSIS (2016)
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
Todd J. Anderson et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention
Hirokazu Konishi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Statins in the treatment of autosomal dominant polycystic kidney disease
Tevfik Ecder
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients
Hao Shen et al.
BMC NEPHROLOGY (2016)
Lowering cholesterol in chronic kidney disease: is it safe and effective?
Muh Geot Wong et al.
EUROPEAN HEART JOURNAL (2015)
The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance
Manya Warrier et al.
CELL REPORTS (2015)
Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis
Diana M. Shih et al.
JOURNAL OF LIPID RESEARCH (2015)
Risk Factor Paradox in CKD and ESRD: Does a Healthy Lifestyle Matter?
Srinivasan Beddhu et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
Wanyin Hou et al.
EUROPEAN HEART JOURNAL (2013)
Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients
Hirokazu Honda et al.
ATHEROSCLEROSIS (2012)
Effects of Fibrates in Kidney Disease
Min Jun et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis
Winfried Maerz et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
Christian Besler et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
History of Discovery Oxidized Low-Density Lipoprotein and Atherosclerosis
Daniel Steinberg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Mediterranean diet improves dyslipidemia and biomarkers in chronic renal failure patients
Khedidja Mekki et al.
FOOD & FUNCTION (2010)
Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD
Michael J. Koren et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Charles Thomas et al.
CELL METABOLISM (2009)
High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response
Andrew J. Murphy et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease
James Shepherd et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis
Alexander S. Goldfarb-Rumyantzev et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2007)
Endothelial and antithrombotic actions of HDL
Chieko Mineo et al.
CIRCULATION RESEARCH (2006)
High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases
C Mineo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD
KPG Harris et al.
KIDNEY INTERNATIONAL (2002)
Share Paper
